Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference

SAN DIEGO, Sept. 24 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the Fifth Annual JMP Securities Healthcare Conference.  The details are as follows:  

Date:  Tuesday, September 28, 2010

Time:  11:00am (EDT)

Location: New York Palace Hotel

Speaker: Graham Cooper, Chief Financial Officer



About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company has filed an NDA with the FDA for its lead investigational product, Contrave®.  The Company's second product, Empatic™, has completed Phase 2 clinical development.  Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches.  Further information about the Company can be found at http://www.Orexigen.com.

SOURCE Orexigen Therapeutics, Inc.

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.